Journal
NEUROLOGY
Volume 95, Issue 19, Pages E2648-E2657Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000010739
Keywords
-
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]
- Department of Defense ADNI (Department of Defense) [W81XWH-12-2-0012]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- AbbVie
- Alzheimer's Association
- Alzheimer's Drug Discovery Foundation
- Araclon Biotech
- BioClinica, Inc.
- Biogen
- Bristol-Myers Squibb Company
- CereSpir, Inc.
- Cogstate
- Eisai Inc.
- Elan Pharmaceuticals, Inc.
- Eli Lilly and Company
- EuroImmun
- F. Hoffmann-La Roche Ltd
- Genentech, Inc.
- Fujirebio
- GE Healthcare
- IXICO Ltd.
- Janssen Alzheimer Immunotherapy Research & Development, LLC
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Lumosity, Lundbeck, Merck Co., Inc.
- Meso Scale Diagnostics, LLC
- NeuroRx Research
- Neurotrack Technologies
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Piramal Imaging
- Servier
- Takeda Pharmaceutical Company
- Transition Therapeutics
- Canadian Institutes of Health Research
- Alzheimer Nederland
- Stichting VUmc fonds
Ask authors/readers for more resources
Objective To investigate the association between discordant beta-amyloid (A beta) PET and CSF biomarkers at baseline and the emergence of tau pathology 5 years later. Methods We included 730 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants without dementia (282 cognitively normal, 448 mild cognitive impairment) with baseline [F-18]florbetapir PET and CSF A beta(42) available. A beta CSF/PET status was determined at baseline using established cutoffs. Longitudinal data were available for [18F]florbetapir (A beta) PET (baseline to 4.3 +/- 1.9 years), CSF (p)tau (baseline to 2.0 +/- 0.1 years), cognition (baseline to 4.3 +/- 2.0 years), and [18F]flortaucipir (tau) PET (measured 5.2 +/- 1.2 years after baseline to 1.6 +/- 0.7 years later). We used linear mixed modeling to study the association between A beta CSF/PET status and tau pathology measured in CSF or using PET. We calculated the proportion of CSF+/PET-participants who during follow-up (1) progressed to A beta CSF+/PET+ or (2) became taupositive based on [18F]flortaucipir PET. Results A beta CSF+/PET+ (n = 318) participants had elevated CSF (p)tau levels and worse cognitive performance at baseline, while CSF+/PET- (n = 80) participants were overall similar to the CSF-/PET- (N = 306) group. Five years after baseline, [18F]flortaucipir PET uptake in the CSF+/PET- group (1.20 +/- 0.13) did not differ from CSF-/PET- (1.18 +/- 0.08, p = 0.69), but was substantially lower than CSF+/PET+ (1.48 +/- 0.44, p < 0.001). Of the CSF+/PET-participants, 21/64 (33%) progressed to A beta CSF+/PET+, whereas only one (3%, difference p < 0.05) became tau-positive based on [18F]flortaucipir PET. Conclusions A beta load detectable by both CSF and PET seems to precede substantial tau deposition. Compared to participants with abnormal A beta levels on both PET and CSF, the CSF+/PET-group has a distinctly better prognosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available